Sponsored by
A new study from Dana-Farber and the Broad Institute, published in Nature Communications, found that 8.9% of pediatric gliomas -- especially low-grade gliomas -- have FGFR gene alterations. An initial retrospective look shows that these tumors may respond to existing FGFR inhibitors. While more trials are needed, this discovery could lead to new precision therapy options for children with pediatric low grade gliomas.